Vistagen (NASDAQ: VTGN) has announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder (SAD).
According to Vistagen, the open label extension portion of PALISADE-4 remains ongoing.
In a statement, Shawn Singh, president and CEO, commented, “The completion of the randomized portion of PALISADE-4 is another important step for our fasedienol Phase 3 program in social anxiety disorder, and we expect to announce topline results this quarter. We extend our sincere thanks to the participants, clinical investigators, site staff, and contract research organization whose hard work, collaboration, and commitment brought this portion of the study to completion.”
